Researchers test if kidney health changes transplant drug dose for leukemia patients
NCT ID NCT05534620
Summary
This study aims to understand how kidney function and race/ethnicity affect how the body processes a drug called treosulfan, which is used to prepare patients for a stem cell transplant. The research involves 36 adults with acute myeloid leukemia or myelodysplastic syndrome who are scheduled for a transplant. The goal is to find the safest and most effective dose for patients with reduced kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
WITHDRAWNNew York, New York, 10021, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
-
University of Illinois
RECRUITINGChicago, Illinois, 60612, United States
Contact Email: •••••@•••••
-
VCU Massey Cancer Center
RECRUITINGRichmond, Virginia, 23298, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.